stoxline Quote Chart Rank Option Currency Glossary
  
Eli Lilly and Company (LLY)
589.25  1.1 (0.19%)    12-06 16:00
Open: 590.74
High: 593.81
Volume: 2,078,158
  
Pre. Close: 588.15
Low: 584.4
Market Cap: 559,379(M)
Technical analysis
2023-12-06 4:22:39 PM
Short term     
Mid term     
Targets 6-month :  731.01 1-year :  853.82
Resists First :  625.86 Second :  731.01
Pivot price 591.23
Supports First :  579.76 Second :  551.26
MAs MA(5) :  587.63 MA(20) :  595.01
MA(100) :  554.43 MA(250) :  450.73
MACD MACD :  1.1 Signal :  2.8
%K %D K(14,3) :  32.4 D(3) :  26.9
RSI RSI(14): 50.2
52-week High :  629.96 Low :  309.2
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ LLY ] has closed above bottom band by 38.2%. Bollinger Bands are 76.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 594.79 - 597.19 597.19 - 599.66
Low: 578.5 - 580.99 580.99 - 583.56
Close: 585.17 - 589.49 589.49 - 593.95
Company Description

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Headline News

Wed, 06 Dec 2023
Eli Lilly & Co. stock outperforms market on strong trading day - MarketWatch

Tue, 05 Dec 2023
Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks - CNBC

Tue, 05 Dec 2023
Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25 - Wccftech

Tue, 05 Dec 2023
Eli Lilly announces U.S. availability of weight loss drug Zepbound (NYSE:LLY) - Seeking Alpha

Tue, 05 Dec 2023
Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity | Eli Lilly and Company - Investors | Eli Lilly and Company

Tue, 05 Dec 2023
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NYSE
Sector:
Healthcare
Industry:
Drug Manufacturers—General
Shares Out 949 (M)
Shares Float 898 (M)
Held by Insiders 0.1 (%)
Held by Institutions 83.9 (%)
Shares Short 5,840 (K)
Shares Short P.Month 6,390 (K)
Stock Financials
EPS 5.55
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.47
Profit Margin 15.5 %
Operating Margin 37.2 %
Return on Assets (ttm) 11.6 %
Return on Equity (ttm) 46.4 %
Qtrly Rev. Growth 36.7 %
Gross Profit (p.s.) 23.07
Sales Per Share 33.78
EBITDA (p.s.) 11.92
Qtrly Earnings Growth 0 %
Operating Cash Flow 5,710 (M)
Levered Free Cash Flow 3,900 (M)
Stock Valuations
PE Ratio 106.17
PEG Ratio 4
Price to Book value 47.21
Price to Sales 17.44
Price to Cash Flow 97.96
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android